Treatment of stimulant use disorder: A systematic review of reviews

Claire Ronsley, Seonaid Nolan, Rod Knight, Kanna Hayashi, Jano Klimas, Alex Walley, Evan Wood, Nadia Fairbairn, Claire Ronsley, Seonaid Nolan, Rod Knight, Kanna Hayashi, Jano Klimas, Alex Walley, Evan Wood, Nadia Fairbairn

Abstract

Aims: Stimulant use disorder contributes to a substantial worldwide burden of disease, although evidence-based treatment options are limited. This systematic review of reviews aims to: (i) synthesize the available evidence on both psychosocial and pharmacological interventions for the treatment of stimulant use disorder; (ii) identify the most effective therapies to guide clinical practice, and (iii) highlight gaps for future study.

Methods: A systematic database search was conducted to identify systematic reviews and meta-analyses. Eligible studies were those that followed standard systematic review methodology and assessed randomized controlled trials focused on the efficacy of interventions for stimulant use disorder. Articles were critically appraised using an assessment tool adapted from Palmeteer et al. and categorized for quality as 'core' or 'supplementary' reviews. Evidence from the included reviews were further synthesized according to pharmacological or non-pharmacological management themes.

Results: Of 476 identified records, 29 systematic reviews examining eleven intervention modalities were included. The interventions identified include: contingency management, cognitive behavioural therapy, acupuncture, antidepressants, dopamine agonists, antipsychotics, anticonvulsants, disulfiram, opioid agonists, N-Acetylcysteine, and psychostimulants. There was sufficient evidence to support the efficacy of contingency management programs for treatment of stimulant use disorder. Psychostimulants, n-acetylcysteine, opioid agonist therapy, disulfiram and antidepressant pharmacological interventions were found to have insufficient evidence to support or discount their use. Results of this review do not support the use of all other treatment options.

Conclusions: The results of this review supports the use of contingency management interventions for the treatment of stimulant use disorder. Although evidence to date is insufficient to support the clinical use of psychostimulants, our results demonstrate potential for future research in this area. Given the urgent need for effective pharmacological treatments for stimulant use disorder, high-quality primary research focused on the role of psychostimulant medications for the treatment of stimulant use disorder is needed.

Conflict of interest statement

No authors have competing interests.

Figures

Fig 1. Flow diagram of the selection…
Fig 1. Flow diagram of the selection and review process for review articles.

References

    1. Uhlmann S, DeBeck K, Simo A, Kerr T, Montaner JS, Wood E. Health and social harms associated with crystal methamphetamine use among street-involved youth in a Canadian setting. Am J Addict. 2014;23(4):393–8. 10.1111/j.1521-0391.2014.12123.x
    1. Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Krajden M, et al. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug Alcohol Depend. 2015;152:272–6. 10.1016/j.drugalcdep.2015.04.005
    1. Operskalski EA, Mack WJ, Strickler HD, French AL, Augenbraun M, Tien PC, et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol. 2008;41(4):255–63. 10.1016/j.jcv.2007.08.021
    1. Darke S, Torok M, Kaye S, Ross J, McKetin R. Comparative rates of violent crime among regular methamphetamine and opioid users: offending and victimization. Addiction. 2010;105(5):916–9. 10.1111/j.1360-0443.2009.02872.x
    1. Saddichha S, Werker GR, Schuetz C, Krausz MR. Stimulants and Cannabis Use Among a Marginalized Population in British Columbia, Canada: Role of Trauma and Incarceration. Int J Offender Ther Comp Criminol. 2015;59(13):1487–98. 10.1177/0306624X14541661
    1. World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). 2019. Available at: .
    1. Darke S, Kaye S, Duflou J. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction. 2017.
    1. NIDA. (2011, March 1). Treatment Statistics. Retrieved from on 2017, July 21.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097 10.1371/journal.pmed.1000097
    1. American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders (5th ed), American Psychiatric Association, Washington, DC: (2013)
    1. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844–59. 10.1111/j.1360-0443.2009.02888.x
    1. Kelly M, Swann C, Killoran A, Naidoo B, Barnett-Paige E, Morgan A. Methodological problems in constructing the evidence base in public health. Health Development Agency Public Health Evidence Steering Group Methodology Reference Group Starter Paper. 2002;9.
    1. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011;11(1):15 10.1186/1471-2288-11-15
    1. Ellis S, Barnett-Page E, Morgan A, Taylor L, Walters R, Goodrich J. HIV prevention: A review of reviews assessing the effectiveness of interventions to reduce the risk of sexual transmission: Evidence briefing 2003.
    1. De Crescenzo F, Ciabattini M, D'Alò GL, De Giorgi R, Del Giovane C, Cassar C, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLoS Med. 2018;15(12):e1002715 10.1371/journal.pmed.1002715
    1. Schumacher JE, Milby JB, Wallace D, Meehan DC, Kertesz S, Vuchinich R, et al. Meta-analysis of day treatment and contingency-management dismantling research: Birmingham Homeless Cocaine Studies (1990–2006). J Consult Clin Psychol. 2007;75(5):823–8. 10.1037/0022-006X.75.5.823
    1. Farronato NS, Dursteler-Macfarland KM, Wiesbeck GA, Petitjean SA. A systematic review comparing cognitive-behavioral therapy and contingency management for cocaine dependence. J Addict Dis. 2013;32(3):274–87. 10.1080/10550887.2013.824328
    1. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008;27(3):309–17. 10.1080/09595230801919494
    1. Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012;5(4):320–31. 10.2174/1874473711205040006
    1. Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend. 2004;74(1):1–13. 10.1016/j.drugalcdep.2003.12.006
    1. Harada T, Tsutomi H, Mori R, Wilson DB. Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders. Cochrane Database Syst Rev. 2018;12:Cd011315 10.1002/14651858.CD011315.pub2
    1. Mills EJ, Wu P, Gagnier J, Ebbert JO. Efficacy of acupuncture for cocaine dependence: a systematic review & meta-analysis. Harm Reduct J. 2005;2(1):4 10.1186/1477-7517-2-4
    1. Gates S, Smith LA, Foxcroft DR. Auricular acupuncture for cocaine dependence. Cochrane Database Syst Rev. 2006(1):Cd005192 10.1002/14651858.CD005192.pub2
    1. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev. 2011(12):Cd002950 10.1002/14651858.CD002950.pub3
    1. Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis. J Gen Intern Med. 2019.
    1. Torrens M, Fonseca F, Mateu G, Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1–22. 10.1016/j.drugalcdep.2004.09.004
    1. Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction. 2019.
    1. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2010(1):Cd007024 10.1002/14651858.CD007024.pub2
    1. Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2015(5):Cd003352 10.1002/14651858.CD003352.pub4
    1. Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2016;3:Cd006306 10.1002/14651858.CD006306.pub3
    1. Alvarez Y, Perez-Mana C, Torrens M, Farre M. Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat. 2013;45(1):1–10. 10.1016/j.jsat.2012.12.013
    1. Kishi T, Matsuda Y, Iwata N, Correll CU. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2013;74(12):e1169–80. 10.4088/JCP.13r08525
    1. Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2015(4):Cd006754 10.1002/14651858.CD006754.pub4
    1. Alvarez Y, Farre M, Fonseca F, Torrens M. Anticonvulsant drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat. 2010;38(1):66–73. 10.1016/j.jsat.2009.07.001
    1. Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016;111(8):1337–46. 10.1111/add.13328
    1. Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:Cd007380 10.1002/14651858.CD007380.pub4
    1. Bhatt M, Zielinski L, Baker-Beal L, Bhatnagar N, Mouravska N, Laplante P, et al. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis. Syst Rev. 2016;5(1):189 10.1186/s13643-016-0370-x
    1. Perez-Mana C, Castells X, Vidal X, Casas M, Capella D. Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. J Subst Abuse Treat. 2011;40(2):109–22. 10.1016/j.jsat.2010.08.012
    1. Sangroula D, Motiwala F, Wagle B, Shah VC, Hagi K, Lippmann S. Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis. Subst Use Misuse. 2017:1–15.
    1. Dursteler KM, Berger EM, Strasser J, Caflisch C, Mutschler J, Herdener M, et al. Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. Subst Abuse Rehabil. 2015;6:61–74. 10.2147/SAR.S50807
    1. Castells X, Kosten TR, Capella D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse. 2009;35(5):339–49. 10.1080/00952990903108215
    1. Nocito Echevarria MA, Andrade Reis T, Ruffo Capatti G, Siciliano Soares V, da Silveira DX, Fidalgo TM. N-acetylcysteine for treating cocaine addiction—A systematic review. Psychiatry Res. 2017;251:197–203. 10.1016/j.psychres.2017.02.024
    1. Garcia-Rodriguez O, Secades-Villa R, Higgins ST, Fernandez-Hermida JR, Carballo JL, Errasti Perez JM, et al. Effects of voucher-based intervention on abstinence and retention in an outpatient treatment for cocaine addiction: a randomized controlled trial. Exp Clin Psychopharmacol. 2009;17(3):131–8. 10.1037/a0015963
    1. Castells X, Kosten TR, Capella D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials.
    1. Kim YH, Schiff E, Waalen J, Hovell M. Efficacy of acupuncture for treating cocaine addiction: a review paper. J Addict Dis. 2005;24(4):115–32. 10.1300/j069v24n04_09
    1. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338–46. 10.1001/jamapsychiatry.2013.2295
    1. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend. 2014;140:92–100. 10.1016/j.drugalcdep.2014.03.033
    1. Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107(7):1297–306. 10.1111/j.1360-0443.2011.03771.x
    1. Perez-Mana C, Castells X, Torrens M, Capella D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013(9):Cd009695 10.1002/14651858.CD009695.pub2
    1. CRISM National Guideline for the Clinical Management of Opioid Use Disorder. 2018. Available at: .
    1. Roberts-Wolfe DJ, Kalivas PW. Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders. CNS Neurol Disord Drug Targets. 2015;14(6):745–56. 10.2174/1871527314666150529144655
    1. Benishek LA, Dugosh KL, Kirby KC, Matejkowski J, Clements NT, Seymour BL, et al. Prize-based contingency management for the treatment of substance abusers: a meta-analysis. Addiction. 2014;109(9):1426–36. 10.1111/add.12589
    1. Kirby KC, Benishek LA, Dugosh KL, Kerwin ME. Substance abuse treatment providers' beliefs and objections regarding contingency management: implications for dissemination. Drug Alcohol Depend. 2006;85(1):19–27. 10.1016/j.drugalcdep.2006.03.010
    1. Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry. 2006;63(2):201–8. 10.1001/archpsyc.63.2.201
    1. Murphy SM, McDonell MG, McPherson S, Srebnik D, Angelo F, Roll JM, et al. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug Alcohol Depend. 2015;153:293–9. 10.1016/j.drugalcdep.2015.05.004
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(3):Cd002209 10.1002/14651858.CD002209.pub2
    1. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109(9):1414–25. 10.1111/add.12633
    1. Sinclair JM, Chambers SE, Shiles CJ, Baldwin DS. Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. Drug Saf. 2016;39(7):627–45. 10.1007/s40264-016-0416-y
    1. Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care. 2011;38(1):41–58. 10.1016/j.pop.2010.11.004
    1. U.S. Department of Justice DEA, Diversion Control Division. National Forensic Laboratory Information System (NFLIS) 2015 Annual Report. 2016. [Internet].
    1. Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug Alcohol Depend. 2016;158:1–7. 10.1016/j.drugalcdep.2015.11.004
    1. Alves P, Sales C, Ashworth M. Does outcome measurement of treatment for substance use disorder reflect the personal concerns of patients? A scoping review of measures recommended in Europe. Drug Alcohol Depend. 2017;179:299–308. 10.1016/j.drugalcdep.2017.05.049
    1. Elliott L, Haddock CK, Campos S, Benoit E. Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities. PLoS One. 2019;14(12):e0225273 10.1371/journal.pone.0225273
    1. Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: diagnostic challenges, patterns of use and health. Curr Opin Psychiatry. 2014;27(4):269–75. 10.1097/YCO.0000000000000069
    1. Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of "twin epidemics": Rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592.
    1. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat. 1999;16(2):163–7. 10.1016/s0740-5472(98)00039-7
    1. Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, et al. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. Neuropsychopharmacology. 2015;40(10):2347–56. 10.1038/npp.2015.83
    1. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26(2):167–80. 10.1016/s0306-4603(00)00098-8
    1. Pettinati HM, Kampman KM, Lynch KG, Xie H, Dackis C, Rabinowitz AR, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav. 2008;33(5):651–67. 10.1016/j.addbeh.2007.11.011
    1. Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013;38(12):2427–38. 10.1038/npp.2013.143
    1. Runarsdottir V, Hansdottir I, Tyrfingsson T, Einarsson M, Dugosh K, Royer-Malvestuto C, et al. Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial. J Addict Med. 2017;11(3):197–204. 10.1097/ADM.0000000000000297
    1. Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, et al. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry. 2014;75(7):757–64. 10.4088/JCP.13m08862
    1. Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 360. United States2009. p. 308–9.
    1. Willyard C. Pharmacotherapy: Quest for the quitting pill. Nature. 2015;522(7557):S53–5. 10.1038/522S53a
    1. Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, Gross A, et al. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J Clin Pharmacol. 2015;55(5):573–83. 10.1002/jcph.450
    1. Miller ML, Aarde SM, Moreno AY, Creehan KM, Janda KD, Taffe MA. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend. 2015;153:29–36. 10.1016/j.drugalcdep.2015.06.014
    1. Palmer RS, Murphy MK, Piselli A, Ball SA. Substance user treatment dropout from client and clinician perspectives: a pilot study. Subst Use Misuse. 2009;44(7):1021–38. 10.1080/10826080802495237

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever